share_log

AIM ImmunoTech Announces Progress In Ampligen Clinical Trials Targeting Pancreatic Cancer And Long-COVID; Upcoming Milestones Over 18 Months Backed By National Cancer Institute, AstraZeneca, And Merck

Benzinga ·  Jan 15 14:14

– Continued execution across Ampligen (rintatolimod) clinical development programs in areas with critical unmet needs, especially in the high-value pancreatic cancer and Long-COVID spaces

– Expected milestones over the course of the next 18 months provide significant value-driving opportunities, including some trials being partially funded by the National Cancer Institute, AstraZeneca and Merck

OCALA, Fla., Jan. 15, 2025 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE:AIM) ("AIM" or the "Company") today highlighted key clinical, regulatory and corporate milestones achieved over 2024 and outlined its expected upcoming milestones.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Comment Comment · Views 358

Recommended

Write a comment